

## References

### S-11

1. Su Y, Chiu W, Hsu C, Chen J, Ng H. Lower in-hospital mortality with plasma exchange than plasmapheresis in a subgroup analysis of 374 lupus patients. *Biomed Res Int.* 2018;1-8.
2. Ranganathan D, John GT. Therapeutic plasma exchange in renal disorders. *Indian J Nephrol.* 2019;29(3):151-159.
3. Harris E, Meiselman H, Moriarty P, et al. Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis. *J Scleroderma Relat Disord.* 2018;3(2):132-152
4. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: The eighth special issue. *J Clin Apher.* 2019;34(3):171-354.
5. National Institute for Health and Care Excellence (NICE). Familial hypercholesterolaemia: Identification and management [CG71]. 2016.
6. Gao C, McCormack C, van der Weyden C, et al. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome. 2019;134(16):1346-1350.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Primary cutaneous lymphomas. Version 1.2021.
8. Thompson G, Parhofer KG. Current role of lipoprotein apheresis. *Curr Atheroscler Rep.* 2019;21(7):26.
9. Goldberg AC, Dunbar RL, Hemphill L, et al. A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. *J Clin Lipidol.*
10. Banerjee S, Luo P, Reda DJ, et al. Plaque regression and endothelial progenitor cell mobilization with intensive lipid elimination regimen (PREMIER). *Circ Cardiovasc Interv.* 2020;13(8):e008933.